País: Austràlia
Idioma: anglès
Font: APVMA (Australian Pesticides and Veterinary Medicines Authority)
CLODRONIC ACID AS DISODIUM CLODRONATE
DECHRA LTD
clodronic acid(51mg/mL)
PARENTERAL LIQUID/SOLUTION/SUSPENSION
CLODRONIC ACID AS DISODIUM CLODRONATE BISPHOSPHONATE Active 51.0 mg/ml
15mL
VM - Veterinary Medicine
MUSCULOSKELETAL SYSTEM
Poison schedule: 4; Withholding period: WHP: DO NOT USE in horses that may be used for human consumption.; Host/pest details: HORSE: [VASCULAR SYSTEM REACTANT]; For the improvement of lameness associtaed with navicular syndrome in horsesNot recommended for use in horses less than 4 years of age or horses with impaired renal function. Use with caution during pregnancy & lactation. See Contraindications, Precautions & Side Effects on label.
Registered
2023-07-01
Product Name: APVMA Approval No: I Label Name: Signal Headings: Constituent Statements: Claims: I Net Contents: I Directions for Use: Restraints: Contraindications: Precautions: OSPHOS 51 MG/ML SOLUTION FOR INJECTION FOR HORSES 69825/115881 OSPHOS 51 MG/ML SOLUTION FOR INJECTION FOR HORSES PRESCRIPTION ANIMAL REMEDY KEEP OUT OF REACH OF CHILDREN FOR ANIMAL TREATMENT ONLY READ SAFETY DIRECTIONS BEFORE OPENING OR USING 51 mg/ml CLODRONIC ACID (as clodronate disodium tetrahydrate 75 mg/ml) For the improvement of lameness associated with navicular syndrome in horses. 15ml DO NOT USE in horses that may be used for human consumption. This product is contraindicated for use in horses with impaired renal function. It is recommended that baseline renal function parameters are obtained before commencing treatment. Water consumption and urine output should be monitored after administration. This product is not recommended for use in horses less than 4 years of age due to the lack of studies on the side effects of OSPHOS on the skeleton of young animals. The efficacy and safety of OSPHOS has not been established in growing animals. Use with caution during pregnancy or lactation. The safety of OSPHOS for administration during pregnancy and lactation has not been established. Therefore, use only according to the benefit/risk assessment by the responsible veterinarian. Medications containing aminoglycosides or tetracyclines should not be administered for 72 hours following administration of OSPHOS due to the potential for the exacerbation of toxicity by a reduction in serum calcium. Concurrent administration of potentially nephrotoxic drugs, such as NSAIDS, should be approached with caution and renal function RLP APPROVED Side Effects: Dosage and Administration: General Directions: should be monitored. Adequate access to drinking water should be provided when using the product. There is potential for impaired micro-fracture healing associated with clodronic acid administration. Studies regarding the safety of administration to Llegiu el document complet